Spondyloarthropathies
Conference Coverage
Oral tofacitinib scores against psoriasis in phase III trial
Key clinical point: Multiple measures of quality of life and disease burden improved similarly in psoriasis patients regardless of whether they...
Conference Coverage
Secukinumab tames psoriatic arthritis in FUTURE 2 trial
Key clinical point: Secukinumab could prove to be a major new therapy for psoriatic arthritis. Major finding: After 24 weeks, a response of at...
Conference Coverage
Few psoriatic arthritis patients achieve minimal disease activity on methotrexate
Key clinical point: It may be time to rethink methotrexate’s role as first-line therapy for psoriatic arthritis. Major finding: Only 17.4% of...
News
TNF-alpha blockers effective in sustaining reduced PsA activity
Key clinical point: A majority of PsA patients seen in a clinical setting can achieve minimal disease activity on TNF-alpha inhibitors. Major...
Conference Coverage
Psoriasis is independently associated with advanced liver fibrosis
Key clinical point: Noninvasive screening for advanced hepatic fibrosis may be in order for older patients with mild psoriasis never treated...
Conference Coverage
Golimumab effective against nonradiographic axial spondyloarthritis with inflammation
Key clinical point: Golimumab was significantly more effective than placebo among patients with nonradiographic axial spondyloarthritis and...
Guidelines
Axial spondyloarthropathy guidelines: NSAIDs and PT first
Conference Coverage
VIDEO: Secukinumab rapidly effective against ankylosing spondylitis
News
Psoriasis: Brodalumab maintains efficacy through 144 weeks
Key clinical point: The investigational interleukin-17 receptor A inhibitor brodalumab maintained strong clinical efficacy throughout 144 weeks of...
Conference Coverage
VIDEO: Collaborative clinic aims at heart of CVD prevention in rheumatic diseases
Conference Coverage
Certolizumab achieves sustained skin improvement in psoriatic arthritis
Key clinical point: Certolizumab pegol maintains sustained improvement in the dermatologic manifestations of psoriatic arthritis through 96 weeks...